Delta Financial Advisors LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Delta Financial Advisors LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,355 shares of the biopharmaceutical company’s stock after selling 40 shares during the quarter. Delta Financial Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,424,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Sachetta LLC lifted its stake in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $26,000. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $28,000. Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 7.48% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on REGN. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,107.25.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $828.42 on Monday. The stock’s 50-day moving average is $1,021.70 and its two-hundred day moving average is $1,038.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market cap of $91.04 billion, a price-to-earnings ratio of 20.50, a price-to-earnings-growth ratio of 3.13 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1-year low of $783.57 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.